Author:
Punekar Salman R.,Shum Elaine,Grello Cassandra Mia,Lau Sally C.,Velcheti Vamsidhar
Abstract
Many decades in the making, immunotherapy has demonstrated its ability to produce durable responses in several cancer types. In the last decade, immunotherapy has shown itself to be a viable therapeutic approach for non-small cell lung cancer (NSCLC). Several clinical trials have established the efficacy of immune checkpoint blockade (ICB), particularly in the form of anti-programmed death 1 (PD-1) antibodies, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies and anti-programmed death 1 ligand (PD-L1) antibodies. Many trials have shown progression free survival (PFS) and overall survival (OS) benefit with either ICB alone or in combination with chemotherapy when compared to chemotherapy alone. The identification of biomarkers to predict response to immunotherapy continues to be evaluated. The future of immunotherapy in lung cancer continues to hold promise with the development of combination therapies, cytokine modulating therapies and cellular therapies. Lastly, we expect that innovative advances in technology, such as artificial intelligence (AI) and machine learning, will begin to play a role in the future care of patients with lung cancer.
Reference192 articles.
1. Edward Jenner And the history of smallpox and vaccination;Riedel;Proc (Bayl Univ Med Cent),2005
2. The toxins of William b. coley and the treatment of bone and soft-tissue sarcomas;McCarthy;Iowa Orthop J,2006
3. Ueber den jetzigen stand der karzinomforschung nederlandsch tijdschrift voor geneeskunde;Ehrlich;Ned Tijdschr voor Geneeskd,1909
4. The immunobiology of cancer immunosurveillance and immunoediting;Dunn;Immunity,2004
5. The three Es of cancer immunoediting;Dunn;Annu Rev Immunol,2004
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献